Navigation Links
Bone Drug Lowers Risk of Breast Cancer Recurrence
Date:5/31/2008

Zometa, used to treat osteoporosis, showed no unanticipated side effects, researchers report

SATURDAY, May 31 (HealthDay News) -- A drug used to treat osteoporosis lowered the risk of breast cancer recurrence in premenopausal women with early breast cancer.

The Austrian researchers also found that women who took Zometa (zoledronic acid) had a 30 percent lower risk of the cancer spreading to the bone, with other benefits as well.

"We found not only an effect on bone metastases, which one might have anticipated, but also on local regional recurrence, distant bone metastases and contralateral breast cancer," said study author Dr. Michael Gnant, a professor of surgery at the Medical University of Vienna. "The indication is that zoledronic acid exerts a benefit through a variety of mechanisms which, all together, create a tumor-hostile environment..."

Gnant, who presented his findings this weekend at the American Society of Clinical Oncology annual meeting in Chicago, spoke at a Saturday news conference. The trial was partially supported by Novartis, which makes Zometa.

Earlier studies had indicated that Zometa can reduce bone loss occurring as a result of cancer treatment, and that it might also have an effect on the cancer itself.

For this trial, researchers randomized 1,803 patients to one of four arms: hormone therapies tamoxifen or Arimidex (anastrozole, an aromatase inhibitor), with or without Zometa.

Tamoxifen stops estrogen from reaching cancer cells while Arimidex interferes with actual production of estrogen. The hormone estrogen fuels breast cancer cells in estrogen-receptor positive tumors.

All patients were undergoing drug-induced ovarian suppression (to stop production of estrogen), had had surgery to remove the primary tumor, and had seen the cancer spread to 10 or fewer lymph nodes. Treatment lasted three years.

After a median follow-up of five years, either hormone therapy plus Zometa reduced the risk of relapse by 36 percent compared with hormone therapy alone. There were no unanticipated side effects, and the drugs were generally well-tolerated.

"The overall outcome of patients in this trial was excellent," Gnant said. "This is reassuring that patients with endocrine [hormone]-response disease, even in premenopause, can be safely treated with adjuvant chemotherapy. The benefit was seen in and outside the bone."

Although about 5 percent of participants had had chemotherapy before surgery to shrink the tumor, none received later chemo. In Europe, breast cancer patients are commonly treated with endocrine therapy alone," said Dr. Joanne Mortimer, vice chairwoman of medical oncology at City of Hope Cancer Center in Duarte, Calif. In the United States, some, but not all, women in this group are treated without chemotherapy.

"This is not a trial about hormones instead of chemo. It's about Zometa," Mortimer said. "We know that this drug improves bone health, but there is also some evidence that it may actually have an effect on cancer cells, and the fact that this was seen in this population is very exciting."

More information

The American Society of Clinical Oncology has more information on breast cancer.



SOURCES: Joanne Mortimer, vice chairwoman, medical oncology, City of Hope Cancer Center, Duarte, Calif.; May 31, 2008, news conference with Michael Gnant, M.D., professor, surgery, Medical University of Vienna, Austria; May 31, 2008, presentation, American Society of Clinical Oncology annual meeting, Chicago


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Brisk Walking Lowers Blood Pressure, Increases Fitness in Obese
2. Calpis AmealPeptide lowers blood pressure in 2 placebo-controlled trials
3. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
4. Aspirin at Bedtime Lowers Blood Pressure
5. The Childrens Heart Foundation Teams Up With ProFlowers(R) to Raise Awareness and Funding for the Leading Birth Defect in America
6. 2-drug blood pressure therapy lowers cardiovascular risk
7. Hospital Testing for Drug-Resistant Infections Dramatically Lowers Mortality Rates and Costs
8. Galichia Heart Hospital Lowers Cost of Bypass to $10K
9. Aggressive Diabetes Therapy Lowers Death Risk, Study Finds
10. Major Community Health Organization Lowers TCO with Ericoms Alternative to Citrix
11. Anti-Inflammatory Drug Improves Glycemia, Lowers Inflammation in Obese, Young Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , ... January 19, 2017 , ... St. Catherine’s Village ... , Siena Center is a skilled nursing facility on the grounds of the St. ... rooms. It recently was voted the best nursing home in Mississippi for the second ...
(Date:1/19/2017)... ... ... The CHP suggests that California drivers can avoid hydroplaning as well as ... the space between themselves and other vehicles, according to a January 3 article ... notes that, rain or shine, drivers should always incorporate safe driving practices in their ...
(Date:1/19/2017)... Marriottsville, MD (PRWEB) , ... January 19, 2017 , ... ... launched six new clients into the US market. , Over the past 20 years ... the past 4 weeks SFI has launched six new clients into the US market. ...
(Date:1/19/2017)... ... 19, 2017 , ... Dr. Maz Ghodsian ... the opening of 3 medical offices specializing specifically in hemorrhoid treatment and ... Angeles (Beverly Hills), Hemorrhoids Center of Newport Beach, and Hemorrhoids Center of ...
(Date:1/18/2017)... , ... January 18, 2017 , ... From a health ... released almost daily linking gut health to chronic disease, mental health and general physical ... ” as an important resolution to consider. , For one Charlottesville restaurant, good gut ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... consumables for the medical and veterinary markets worldwide, has ... for the third quarter fiscal year 2017, ended December ... ET on Thursday, January 26, 2017.  The Company will ... 2017 after the market closes on Thursday, January 26, ...
(Date:1/19/2017)... Massachusetts , January 19, 2017 ... ) announced that the U.S. Food and Drug Administration ... of a New Drug Application (NDA) for SHP465, a ... evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder ... on or around June 20, 2017, the designated Prescription ...
(Date:1/19/2017)... , January 19, 2017 ... administration appears serious about reducing the FDA,s regulatory ... innovation in the medical drug industry, many of ... with new clinical trials and development of advanced ... forging ahead with recent developments include:  Moleculin Biotech, ...
Breaking Medicine Technology: